Background: Ambrisentan is an ETA-selective endothelin receptor antagonist approved for the treatment of pulmonary arterial hypertension (PAH). ATHENA-1 was an open-label efficacy and safety study of the addition of ambrisentan therapy to PAH patients with a sub-optimal response to phosphodiesterase-5 inhibitor (PDE5i) therapy.
Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review ... pulmonary arterial hypertension: a review. ... ATHENA, Study of Add-on Ambrisentan Therapy to Background.
ATHENA-1. In an open-label efficacy and safety . ... human hepatocytes study of ERAs (ambrisentan, darusentan, bosentan and sitaxsentan), it was . demonstrated that ambrisentan had little or no .
The ATHENA-1 study describes the safety and efficacy of the addition of ambrisentan in this patient population. ... Ambrisentan is a selective endothelin receptor antagonist approved for the treatment of idiopathic, heritable PAH and connective tissue disease-associated PAH. ... The aim of this study was to assess the cost effectiveness of ...
CONCLUSION: The ambrisentan label change resulted in a significant reduction (69% on average) in the frequency of LFTs, leading to time and indirect cost savings across PAH providers and specialty pharmacies surveyed, as well as direct cost savings for payers. The ambrisentan label reflects a unique FDA position; the removal of the monthly LFT ...
Nevirapine was approved for medical use in the United States in 1996. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is available as a generic medication. The wholesale cost in the developing world is US$2.16 to $16.62 per month as of 2014.
Sleep apnea, also spelled sleep apnoea, is a sleep disorder characterized by pauses in breathing or periods of shallow breathing during sleep. Each pause can last for a few seconds to a few minutes and they happen many times a night. In the most common form, this follows loud snoring.
Global Ambrisentan Market 2018-2025 Confucius Pharmceutical, Megafine, Gilead Sciences ... Gemalto, Giesecke Devrient, Watchdata, Athena. Apex Market Research October 19, 2018. 0 0 2 minutes read. Global Transit Cards Market 2018-2025 report delivers a comprehensive research based study of the market along with the market share, forecast data ...
INTRODUCTION. Pulmonary hypertension is a chronic disorder caused by changes in the pulmonary vasculature that results in an increase in blood pressure in the lungs. 1 Several complex mechanisms are proposed to play roles in the pathophysiology of this condition, including the up-regulation of endothelin production and the down-regulation of nitric oxide and prostacyclin.
Global Ambrisentan Market 2018-2025 Confucius Pharmceutical, Megafine, Gilead Sciences ... Global Magneto Hydrodynamic Pumps Market 2018-2025 Athena, KSB, Ikausa Magneto Hydrodynamic Pumps Market 2018-2025. ... Global Market Study Magneto Hydrodynamic Pumps Market ...
10/16/2014 · The ATHENA-1 study is an open-label, multicenter study evaluating the effect of ambrisentan in patients with pulmonary arterial hypertension and a suboptimal response to monotherapy with a PDE-5 inhibitor.
Also underway is the ATHENA-1 study, which will evaluate changes in pulmonary haemodynamics following addition of ambrisentan to treatment regimens in patients with sub-optimal response to maintenance PD5-inhibitor therapy (sildenafil or tadalafil).
Multinational, Placebo-Controlled, Parallel-Groups Study to Evaluate the Safety and Efficacy of Intramuscular ... Cost-Effectiveness of Alirocumab Based on ... Ambrisentan After Fontan Surgery CH.APS.09 - CHD Surgery and Interventions Jennifer Li, MD, Christoph Hornik, MD
Background and Purpose:The diverse causes of right-sided heart failure (RHF) include, among others, primary cardiomyopathies with right ventricular (RV) involvement, RV ischemia and infarction, volume loading caused by cardiac lesions associated with congenital heart disease and valvular pathologies, and pressure loading resulting from pulmonic stenosis or pulmonary hypertension from a variety ...
INTRODUCTION — Early identification and treatment of pulmonary hypertension (PH) is generally suggested because advanced disease may be less responsive to therapy .Treatment begins with a baseline assessment of disease severity, followed by primary therapy. Primary therapy is directed at the underlying cause of the PH.
Disease Progression Subject Areas on Research "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
School of Medicine; Internal Medicine; Overview; Fingerprint; Network; Profiles (42); Research Output (468); Research Output 1978 2019 424
Double-Blind Method Subject Areas on Research 'Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation'.
dosage/cost, 90 for chorea, 7 stability of drug after expiration date, 101 Amaryl. SeeGlimepiride Ambrisentan, 87 Amiodarone, 78, 79 Amitriptyline drug interactions with, 76 for fibromyalgia, 45 Amlodipine, 9, 47 ... ATHENA, 79 Avon Longitudinal Study of Parents and Children, 103 Baltimore Memory Study, 103 COGENT, 2 CONFIRMS, 37 CREDO, 2
PubFacts seeks to make the world's scientific research easy to locate, access, and collaborate on.